Myrio Therapeutics

Myrio Therapeutics (formerly Affinity BIO) is a privately owned biotechnology company based in Melbourne, Australia. Founded in 2009 by biotech entrepreneurs Ben Kiefel and Matt Beasley, Myrio began building and developing what would become the world’s fastest antibody discovery platform. The resulting technology from Myrio, Retained Display (ReD), has been tested in campaigns targeting some of the most challenging diagnostic and laboratory reagent objectives the team could identify.Myrio is collaborating with some of the world's leading institutions to research various targets, including endogenous retroviruses and patient-specific neoantigens. These collaborations demonstrate the utility of Myrio’s human scFv in bispecific and CAR-T formats. Myrio’s strategy is to partner with collaborators to develop therapies for specific targets while establishing spin-offs or joint ventures to clinically develop specific assets.